Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in...

Full description

Bibliographic Details
Main Authors: Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Hideki Suganami, Shun Ishibashi, on Behalf of the K-877 Study Group
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:International Journal of Molecular Sciences
Subjects:
high-density lipoprotein cholesterol
K-877
pemafibrate
renal dysfunction
safety
selective PPARα modulator
triglyceride
Online Access:https://www.mdpi.com/1422-0067/20/3/706

Similar Items

Similar Items